JP2009541396A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541396A5 JP2009541396A5 JP2009517002A JP2009517002A JP2009541396A5 JP 2009541396 A5 JP2009541396 A5 JP 2009541396A5 JP 2009517002 A JP2009517002 A JP 2009517002A JP 2009517002 A JP2009517002 A JP 2009517002A JP 2009541396 A5 JP2009541396 A5 JP 2009541396A5
- Authority
- JP
- Japan
- Prior art keywords
- dystonia
- pharmaceutical composition
- muscle
- treatment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010118 dystonia Diseases 0.000 claims 24
- 210000003205 muscle Anatomy 0.000 claims 24
- 208000014094 Dystonic disease Diseases 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 238000011282 treatment Methods 0.000 claims 22
- 108030001720 Bontoxilysin Proteins 0.000 claims 6
- 208000008238 Muscle Spasticity Diseases 0.000 claims 6
- 229940053031 botulinum toxin Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010040954 Skin wrinkling Diseases 0.000 claims 5
- 210000004907 gland Anatomy 0.000 claims 5
- 231100000189 neurotoxic Toxicity 0.000 claims 5
- 230000002887 neurotoxic effect Effects 0.000 claims 5
- 208000018198 spasticity Diseases 0.000 claims 5
- 210000003813 thumb Anatomy 0.000 claims 5
- 208000008454 Hyperhidrosis Diseases 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 230000037303 wrinkles Effects 0.000 claims 4
- 241000193155 Clostridium botulinum Species 0.000 claims 3
- 206010044074 Torticollis Diseases 0.000 claims 3
- 238000005452 bending Methods 0.000 claims 3
- 230000002920 convulsive effect Effects 0.000 claims 3
- 230000037315 hyperhidrosis Effects 0.000 claims 3
- 230000003447 ipsilateral effect Effects 0.000 claims 3
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 235000004252 protein component Nutrition 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000002146 bilateral effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000004720 cerebrum Anatomy 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 210000003499 exocrine gland Anatomy 0.000 claims 2
- 210000003414 extremity Anatomy 0.000 claims 2
- 210000003811 finger Anatomy 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000018197 inherited torticollis Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000030214 innervation Effects 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000003371 toe Anatomy 0.000 claims 2
- 210000000689 upper leg Anatomy 0.000 claims 2
- 241000567030 Ampulloclitocybe clavipes Species 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010059237 Auriculotemporal syndrome Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 208000019352 Blepharospasm-oromandibular dystonia syndrome Diseases 0.000 claims 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims 1
- 206010072043 Central nervous system haemorrhage Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 241000270722 Crocodylidae Species 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000004041 Gustatory Sweating Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 201000005190 Meige syndrome Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 1
- 241000223503 Platysma Species 0.000 claims 1
- 206010035628 Pleurothotonus Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 208000008630 Sialorrhea Diseases 0.000 claims 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 1
- 206010058571 Spinal cord infarction Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 206010042364 Subdural haemorrhage Diseases 0.000 claims 1
- 206010043101 Talipes Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000007293 brain stem infarction Diseases 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 201000011228 clubfoot Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000004709 eyebrow Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 210000001097 facial muscle Anatomy 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 210000002683 foot Anatomy 0.000 claims 1
- 210000000245 forearm Anatomy 0.000 claims 1
- 210000001061 forehead Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000002851 oromandibular dystonia Diseases 0.000 claims 1
- 230000037392 palmar hyperhidrosis Effects 0.000 claims 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 claims 1
- 230000036563 plantar hyperhidrosis Effects 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 201000002849 spasmodic dystonia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001364 upper extremity Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81775606P | 2006-06-29 | 2006-06-29 | |
| US60/817,756 | 2006-06-29 | ||
| PCT/EP2007/005754 WO2008000490A1 (en) | 2006-06-29 | 2007-06-28 | High frequency application of neurotoxic component of botulinum toxin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201656A Division JP2014015476A (ja) | 2006-06-29 | 2013-09-27 | ボツリヌス毒素の神経毒成分の高頻度適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009541396A JP2009541396A (ja) | 2009-11-26 |
| JP2009541396A5 true JP2009541396A5 (enExample) | 2012-06-21 |
| JP5897784B2 JP5897784B2 (ja) | 2016-03-30 |
Family
ID=38462381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009517002A Active JP5897784B2 (ja) | 2006-06-29 | 2007-06-28 | ボツリヌス毒素の神経毒成分の高頻度適用 |
| JP2013201656A Withdrawn JP2014015476A (ja) | 2006-06-29 | 2013-09-27 | ボツリヌス毒素の神経毒成分の高頻度適用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201656A Withdrawn JP2014015476A (ja) | 2006-06-29 | 2013-09-27 | ボツリヌス毒素の神経毒成分の高頻度適用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8557255B2 (enExample) |
| EP (2) | EP2032157A1 (enExample) |
| JP (2) | JP5897784B2 (enExample) |
| KR (3) | KR20140142377A (enExample) |
| CN (1) | CN101460190A (enExample) |
| AR (1) | AR061669A1 (enExample) |
| AU (1) | AU2007264008B2 (enExample) |
| BR (1) | BRPI0713061A2 (enExample) |
| CA (1) | CA2654214C (enExample) |
| CL (1) | CL2007001911A1 (enExample) |
| IL (1) | IL195201A (enExample) |
| MX (1) | MX2009000253A (enExample) |
| RU (1) | RU2453333C2 (enExample) |
| TW (1) | TWI519310B (enExample) |
| UY (1) | UY30450A1 (enExample) |
| WO (1) | WO2008000490A1 (enExample) |
| ZA (1) | ZA200808491B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP1985276A1 (en) * | 2007-04-26 | 2008-10-29 | Merz Pharma GmbH & Co. KGaA | Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy |
| CN101687018A (zh) * | 2007-06-01 | 2010-03-31 | 德国麦氏大药厂 | 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法 |
| US7473429B1 (en) * | 2007-07-27 | 2009-01-06 | Renfroe J Ben | Method for treatment of laminitis in animals |
| US8455459B2 (en) | 2007-08-02 | 2013-06-04 | Medicis Pharmaceutical Corporation | Method of applying an injectable filler |
| US20090204101A1 (en) * | 2007-08-20 | 2009-08-13 | Wortzman Mitchell S | Method of applying an injectable filler |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| ES2571792T3 (es) * | 2008-03-31 | 2016-05-26 | The Chemo-Sero-Therapeutic Res Inst | Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1 |
| JP5746624B2 (ja) | 2008-08-29 | 2015-07-08 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | 変化した持続性を有するクロストリジウム性神経毒 |
| ES2426667T3 (es) * | 2008-09-09 | 2013-10-24 | Susanne Grafe | Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano) |
| EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| EP2246065A1 (en) | 2009-04-29 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Intrastriatal botulinum toxin therapy |
| WO2011023213A1 (en) * | 2009-08-28 | 2011-03-03 | Merz Pharma Gmbh & Co. Kgaa | Modified chemodenervating agents |
| JP5951490B2 (ja) * | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| KR101134146B1 (ko) | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| EP2399601A1 (en) | 2010-06-24 | 2011-12-28 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin therapy |
| EP2627318B1 (en) | 2010-10-12 | 2017-08-16 | Merz Pharma GmbH & Co. KGaA | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| RU2454170C1 (ru) * | 2011-02-21 | 2012-06-27 | Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения спастичности мышц у больных с позвоночно-спинномозговой травмой |
| MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
| RU2535115C1 (ru) | 2013-05-15 | 2014-12-10 | Бости Трейдинг Лтд | Фармацевтический состав, содержащий нейротоксин ботулина |
| CN105658662B (zh) * | 2013-07-30 | 2022-05-27 | 莫茨制药有限及两合公司 | 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用 |
| EP3046470B1 (en) | 2013-09-20 | 2022-02-23 | MDDT Inc. | Diagnosing and treating movement disorders |
| WO2015039206A1 (en) * | 2013-09-20 | 2015-03-26 | Mddt Inc. | Diagnosing and treating movement disorders |
| EP3154572A1 (en) * | 2014-06-13 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
| EP3154635A1 (en) * | 2014-06-13 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| ES2762951T3 (es) * | 2015-04-24 | 2020-05-26 | Consiglio Nazionale Ricerche | Nuevo uso terapéutico de la neurotoxina botulínica serotipo A |
| WO2018146550A1 (en) * | 2017-02-10 | 2018-08-16 | De Maio Domingos Mauricio | Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same |
| EP3927355A1 (en) * | 2019-02-21 | 2021-12-29 | Merz Pharma GmbH & Co. KGaA | Novel uses of botulinum neurotoxin for the treatment of tremor |
| RU2721300C2 (ru) * | 2019-10-17 | 2020-05-18 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US11090371B1 (en) | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| AU2020365148B2 (en) | 2019-10-18 | 2022-10-27 | Penland Foundation | Botulinum toxin for use in treatment |
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US11738071B2 (en) | 2021-07-12 | 2023-08-29 | Penland Foundation | Treatment of acute and chronic kidney disease |
| WO2021137667A1 (ko) * | 2019-12-30 | 2021-07-08 | 주식회사 에이티지씨 | 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888977A (en) * | 1973-02-01 | 1975-06-10 | Murray J Sanders | Modified neurotoxin |
| US4932936A (en) * | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
| EP1099445A3 (en) * | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| US7037680B2 (en) * | 1993-09-21 | 2006-05-02 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
| US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
| US8187612B2 (en) * | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
| US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| EP1602379A1 (en) * | 1993-12-28 | 2005-12-07 | Allergan, Inc. | Botulinum toxin B for treating spastic muscle |
| US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| CA2505933C (en) * | 1997-07-15 | 2008-09-30 | Richard A. Schmidt | Use of botulinum toxin for treating urinary incontinence |
| DK1023410T3 (da) * | 1998-07-07 | 2006-08-14 | Sun Chemical Corp | Kationisk hærdelige litografiske trykfarver med lave indhold af flygtige organiske forbindelser |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| JP3694238B2 (ja) | 1998-09-11 | 2005-09-14 | バークシャー ラボラトリーズ，インコーポレイティド | 音響エネルギーを使用する誘導電流の生成および感知 |
| DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US6348434B1 (en) * | 1999-07-01 | 2002-02-19 | Basf Aktiengesellschaft | Herbicidal emulsifiable concentrate |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| JP2003512603A (ja) | 1999-10-05 | 2003-04-02 | テクノロジィ ファイナンス コーポレイション（プロプライエタリー） リミテッド | 回転軸におけるトルクによるねじれの測定 |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| AU770851B2 (en) | 1999-10-14 | 2004-03-04 | Mine Safety Appliances Company | Lanyard with integral fall arrest energy absorber |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
| DE10043982A1 (de) * | 2000-09-05 | 2002-03-14 | Armin Maurer | Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares |
| US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
| US7226605B2 (en) * | 2001-07-27 | 2007-06-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
| US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| US20050106183A1 (en) * | 2002-01-31 | 2005-05-19 | Lamb Gregory B. | Method of treating pain |
| US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
| US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US7300412B2 (en) * | 2002-05-10 | 2007-11-27 | Hospital For Joint Diseases | Methods for therapeutic treatment of carpal tunnel syndrome |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| WO2003101483A1 (en) * | 2002-05-31 | 2003-12-11 | Solux Corporation | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
| US6776991B2 (en) * | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| AU2003227362A1 (en) | 2002-08-06 | 2004-03-03 | Genox Research, Inc. | Method of examining atopic dermatitis |
| US7824693B2 (en) * | 2002-08-19 | 2010-11-02 | Ira Sanders | Treatment of fine wrinkles with clostridia neurotoxins |
| US7288259B2 (en) * | 2002-08-19 | 2007-10-30 | Ira Sanders | Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| US20040115222A1 (en) * | 2002-09-06 | 2004-06-17 | Michael Kane | Method for reduction of wrinkles |
| EP1398907B1 (de) * | 2002-09-10 | 2010-12-08 | Siemens Aktiengesellschaft | Verfahren zur Kontrolle von Übertragungsressourcen eines paketorientierten Kommunikationsnetzes bei Topologieänderungen |
| US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US20050042775A1 (en) * | 2003-08-21 | 2005-02-24 | Nicholas Pomato | Botulinum antitoxin compositions and methods |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US20050144029A1 (en) * | 2003-12-31 | 2005-06-30 | Rakowski Richard R. | Systems and methods for aesthetic improvement |
| ATE451117T1 (de) * | 2004-01-05 | 2009-12-15 | Botulinum Toxin Res Ass Inc | Verfahren zur verwendung von botulinustoxin zur behandlung von hypervolämischer lippendeformität (lippen-ektropion) |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
| BRPI0513850A (pt) * | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| CA2518650A1 (en) * | 2004-09-10 | 2006-03-10 | Dimitrios Dimitrakoudis | Clostridium botulinum toxin formulation and method for reducing weight |
| EP1799254A1 (en) * | 2004-09-27 | 2007-06-27 | Merz Pharma GmbH & Co.KGaA | Clostridial neurotoxins for use in tissue healing |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
| US20080220021A1 (en) * | 2005-02-14 | 2008-09-11 | Pankaj Modi | Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis |
| WO2006094539A1 (en) * | 2005-03-03 | 2006-09-14 | Université Catholique de Louvain | Methods and compositions for the treatment of cancer |
| US20060269574A1 (en) * | 2005-05-31 | 2006-11-30 | De Beer Johann F | Method of repairing tendons by surgery |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| US20070128226A1 (en) * | 2005-12-01 | 2007-06-07 | Philip Radovic | Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot |
| US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
| WO2008039245A2 (en) * | 2006-04-27 | 2008-04-03 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
| EP1985276A1 (en) * | 2007-04-26 | 2008-10-29 | Merz Pharma GmbH & Co. KGaA | Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy |
| CN101687018A (zh) * | 2007-06-01 | 2010-03-31 | 德国麦氏大药厂 | 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法 |
| US8586081B2 (en) * | 2007-09-20 | 2013-11-19 | University Of Massachusetts | Detoxified recombinant botulinum neurotoxin |
| US9038912B2 (en) * | 2007-12-18 | 2015-05-26 | Microsoft Technology Licensing, Llc | Trade card services |
| JP5746624B2 (ja) * | 2008-08-29 | 2015-07-08 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | 変化した持続性を有するクロストリジウム性神経毒 |
| EP2398824B1 (en) * | 2009-02-19 | 2018-12-26 | Merz Pharma GmbH & Co. KGaA | Means and methods for manufacturing highly pure neurotoxin |
| AU2010267963B2 (en) * | 2009-07-02 | 2015-09-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxins exhibiting shortened biological activity |
| HUE029697T2 (en) * | 2010-01-22 | 2017-03-28 | Merz Pharma Gmbh & Co Kgaa | To quantify the activity of clostridial neurotoxin in an in vitro assay |
| JP2015504304A (ja) * | 2011-11-09 | 2015-02-12 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | ポリ−グリシンを伴う修飾神経毒及びその使用 |
| CN105658662B (zh) * | 2013-07-30 | 2022-05-27 | 莫茨制药有限及两合公司 | 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用 |
-
2007
- 2007-06-27 AR ARP070102861A patent/AR061669A1/es unknown
- 2007-06-28 KR KR1020147032748A patent/KR20140142377A/ko not_active Ceased
- 2007-06-28 EP EP07764931A patent/EP2032157A1/en not_active Ceased
- 2007-06-28 UY UY30450A patent/UY30450A1/es not_active Application Discontinuation
- 2007-06-28 JP JP2009517002A patent/JP5897784B2/ja active Active
- 2007-06-28 BR BRPI0713061-9A patent/BRPI0713061A2/pt not_active IP Right Cessation
- 2007-06-28 AU AU2007264008A patent/AU2007264008B2/en active Active
- 2007-06-28 RU RU2009102848/15A patent/RU2453333C2/ru active
- 2007-06-28 WO PCT/EP2007/005754 patent/WO2008000490A1/en not_active Ceased
- 2007-06-28 CL CL200701911A patent/CL2007001911A1/es unknown
- 2007-06-28 CN CNA2007800206820A patent/CN101460190A/zh active Pending
- 2007-06-28 TW TW096123534A patent/TWI519310B/zh active
- 2007-06-28 MX MX2009000253A patent/MX2009000253A/es active IP Right Grant
- 2007-06-28 EP EP12001562A patent/EP2484373A1/en not_active Withdrawn
- 2007-06-28 KR KR1020157031398A patent/KR20150126979A/ko not_active Ceased
- 2007-06-28 CA CA2654214A patent/CA2654214C/en active Active
- 2007-06-28 KR KR1020097001114A patent/KR20090027732A/ko not_active Ceased
- 2007-06-29 US US11/824,393 patent/US8557255B2/en active Active
-
2008
- 2008-10-06 ZA ZA200808491A patent/ZA200808491B/xx unknown
- 2008-11-10 IL IL195201A patent/IL195201A/en active IP Right Grant
-
2013
- 2013-09-13 US US14/026,289 patent/US9095523B2/en active Active
- 2013-09-27 JP JP2013201656A patent/JP2014015476A/ja not_active Withdrawn
-
2015
- 2015-06-25 US US14/749,834 patent/US9572871B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541396A5 (enExample) | ||
| RU2009102848A (ru) | Высокая частота введения нейротоксического компонента ботулотоксина | |
| Marciniak | Poststroke hypertonicity: upper limb assessment and treatment | |
| JP2011506511A5 (enExample) | ||
| CN101917960A (zh) | 肉毒杆菌毒素复合物的神经毒成分在减少或预防副作用中的应用 | |
| Yang et al. | Cortical reorganization induced by body weight–supported treadmill training in patients with hemiparesis of different stroke durations | |
| WO2011160826A1 (en) | Botulinum toxin therapy | |
| Teachey et al. | Tinnitus of myofascial origin | |
| Umar et al. | Effect of botulinum toxin A & task-specific training on upper limb function in post-stroke focal dystonia | |
| JP2014529395A5 (enExample) | ||
| Sławek et al. | Botulinum toxin type-A preparations are not the same medications—clinical studies (Part 2) | |
| Gordon | The role of botulinus toxin type A in treatment–with special reference to children | |
| Ahmed et al. | Dalak (massage) in Unani medicine: a review | |
| ZHANG | Tuina for infant congenital muscular torticollis: a randomized controlled trial | |
| RU2344805C2 (ru) | Способ лечения заболеваний, травм периферической нервной системы, их последствий и последствий нарушения спинального мозгового кровообращения и спинальных травм | |
| Jia et al. | Treatment of 40 cases of post-apoplectic dysphagia by acupuncture plus rehabilitation exercise | |
| Guidubaldi et al. | Clinical use of botulinum neurotoxin: neuromuscular disorders | |
| Kralj | The use of botulinum toxin in medicine | |
| Agarwal et al. | The effect of move kinetic taping with conventional physiotherapy management on pain and grip strength associated with elbow performance in patient with lateral epicondylitis | |
| Çekmece et al. | Efficacy of Kinesio® tapes in obstetrical brachial plexus injury: A randomized controlled trial | |
| Xiao et al. | Effect Analysis of Botox Combined with Rehabilitation Training on Upper Limb Spasm after Hemiplegia. | |
| Wissel | Treatment of spasticity-related pain syndromes | |
| Topp et al. | Adhesion of Three Brands of Elastic Therapeutic Tape | |
| Zhao | Rehabilitation Therapy of Neurological Training of Facial Paralysis | |
| Zhang | Comparison of the Curative Effects between Early Rehabilitation and Convalescent Rehabilitation in Weightlifter after Elbow Fracture Surgery Based on Ecological Sports Concept. |